Valuation: Innate Pharma

Market Cap 77.58M 85.18M 71.49M 65.03M 122M 7.89B 128M 870M 346M 4.31B 320M 313M 13.52B P/E 2026 *
7.06x
P/E 2027 * 0.91x
Enterprise Value 22.58M 24.8M 20.81M 18.93M 35.51M 2.3B 37.32M 253M 101M 1.25B 93.03M 91.07M 3.94B EV / Sales 2026 *
0.48x
EV / Sales 2027 * -0.86x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Innate Pharma

1 day-8.51%
1 week-31.00%
Current month-34.08%
1 month-38.67%
3 months-53.48%
6 months-57.76%
Current year-48.31%
1 week 0.81
Extreme 0.806
1.29
1 month 0.81
Extreme 0.806
1.42
Current year 0.81
Extreme 0.806
2.33
1 year 0.81
Extreme 0.806
2.33
3 years 0.81
Extreme 0.806
2.8
5 years 0.81
Extreme 0.806
4.84
10 years 0.81
Extreme 0.806
15.83
Manager TitleAgeSince
Chief Executive Officer - 01/11/2024
Director of Finance/CFO 51 01/04/2021
Chief Tech/Sci/R&D Officer 57 01/09/2026
Director TitleAgeSince
Chairman 66 01/01/2024
Director/Board Member 65 27/04/2015
Director/Board Member 60 19/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/8/26
BPIFrance Participations SA /PRIVATE EQUITY/
BuyCompany 1,764,705 1.8789%
20/1/26 Buy

Executive/Senior Manager

50,000 0.0542%
16/1/26 Buy

Chief Financial Officer

50,000 0.0542%
Change 5-day change 1-year change 3-year change Capi.($)
-8.51%-31.00%-48.38%-64.69% 85.18M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -2.09%-4.19%+25.46%+151.26% 40B
Weighted average by Cap. -1.48%-1.86%+32.14%+150.85%

Financials

2026 *2027 *
Net sales 47.42M 52.06M 43.69M 39.75M 74.57M 4.82B 78.37M 532M 211M 2.63B 195M 191M 8.26B 90M 98.81M 82.93M 75.43M 142M 9.15B 149M 1.01B 401M 5B 371M 363M 15.68B
Net income -859K -943K -792K -720K -1.35M -87.33M -1.42M -9.63M -3.83M -47.7M -3.54M -3.46M -150M 12.46M 13.68M 11.48M 10.45M 19.6M 1.27B 20.6M 140M 55.55M 692M 51.34M 50.26M 2.17B
Net Debt -55M -60.39M -50.68M -46.1M -86.48M -5.59B -90.89M -617M -245M -3.05B -227M -222M -9.59B -155M -170M -143M -130M -244M -15.77B -256M -1.74B -691M -8.61B -639M -625M -27.03B
Projected Income Statement - Annual - Innate Pharma
Logo Innate Pharma
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - government financing for research expenditure (68.9%); - revenues from collaboration and licensing agreements (31%); - other (0.1%). At the end of 2025, the company had a portfolio of 8 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 3 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas, IPH5201 for the treatment of cancer and IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia) and 4 in phase I (IPH4502 and IPH5301 for the treatment of solid tumours, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).
Employees
120
Date Price Change Volume
20/11/26 EUR 0.8280 -8.51% 1,245,224
19/11/26 EUR 0.9050 -8.40% 1,577,232
18/11/26 EUR 0.9880 -18.08% 1,895,904
17/11/26 EUR 1.206 -2.43% 393,886
16/11/26 EUR 1.236 +3.00% 478,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Innate Pharma
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8280EUR
Average target price
5.933EUR
Spread / Average Target
+616.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Innate Pharma